All In MedTech

Device Trial Radar · NCT07816640

Renal Oxygenation-Guided AKI Reduction Trial

Effect of Renal Oxygenation-Guided Perioperative Management on Acute Kidney Injury After Elective Hepatectomy: A Multicenter, Randomized, Controlled, Parallel-Group Superiority Trial

Last checked: Nov 21, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 1,200 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

1,200

Planned (sponsor's estimate)

Start

Nov 20, 2026

Primary completion

Nov 30, 2027

Study completion Dec 30, 2027

Sponsor

Lead sponsor
Chinese PLA General HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 14, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Prevention
FDA-regulated device
Yes
Who can join
All sexes, from 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Acute kidney injury (AKI) is a common complication after major liver surgery. This study will evaluate whether intraoperative management guided by renal regional oxygen saturation (RrSO₂), measured using near-infrared spectroscopy, can reduce postoperative acute kidney injury in adults undergoing elective hepatectomy. Approximately 1,200 participants at about 20 hospitals in China will be randomly assigned in a 1:1 ratio to RrSO₂-guided management or usual perioperative care. All participants will undergo continuous bilateral renal RrSO₂ monitoring. In the intervention group, RrSO₂ values will be visible to the anesthesia team, and a decrease of 10% or more from baseline on either side will trigger a standardized assessment and stepwise management algorithm. In the control group, RrSO₂ data will be recorded but concealed from the clinical team and will not guide treatment. The primary outcome is AKI within 7 days after surgery or before hospital discharge, whichever occurs first, based on Kidney Disease: Improving Global Outcomes serum creatinine criteria or initiation of renal replacement therapy.

Conditions

  • Acute Kidney Injury
  • Hepatectomy

Interventions

  • INVOS 5100C regional oxygen saturation monitoring systemDevice

    A near-infrared spectroscopy system will be used to continuously record bilateral renal regional oxygen saturation from before anesthesia induction until the end of the intraoperative monitoring period. The device is used in both study arms; display of the values differs by randomized allocation.

  • RrSO2-guided perioperative managementOther

    When either renal RrSO2 decreases by at least 10% from its side-specific baseline, signal artifact and sensor displacement will first be excluded. The anesthesiologist will then assess and treat reversible causes using clinically appropriate measures that may include a small isotonic crystalloid bolus based on goal-directed volume assessment, titrated norepinephrine, dobutamine, treatment of hemodynamically significant bradycardia, optimization of ventilation and oxygenation, and red blood cell transfusion when predefined criteria are met. RrSO2 and hemodynamic responses will be reassessed after each action.

  • Usual perioperative managementOther

    Perioperative anesthesia and hemodynamic management will follow current clinical practice and institutional standards. Renal RrSO2 values will remain hidden and will not be used for clinical decisions.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of postoperative acute kidney injuryTime frame: From the end of surgery through postoperative day 7 or hospital discharge, whichever occurs first

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China

19 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.